FIELD: biotechnology.
SUBSTANCE: group of inventions relates to biotechnology and can be used in medicine and pharmaceutical industry. Method for regioselective chemical N-terminal PEGylation of thymosin beta 4. By this method monoconjugate of PEG with thymosin beta 4 is obtained, having improved pharmacokinetic properties. Modification of N-terminal alpha amino group of thymosin beta 4 is confirmed.
EFFECT: use of invention enables to obtain monoPEGylated thymosin beta 4 with high output.
2 cl, 4 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COVALENT MONOKONJUGAT OF HEXANOIC ACID WITH THYMOSIN BETA 4, RESISTANT TO DEGRADATION IN A STREAM OF BLOOD, AND METHOD FOR PRODUCTION THEREOF | 2015 |
|
RU2604686C2 |
| METHOD OF PRODUCING MONO CONJUGATE OF POLYSIALIC ACID WITH THYMOSIN BETA 4 AND COVALENT MONO CONJUGATE OF POLYSIALIC ACID WITH THYMOSIN BETA 4, RESISTANT TO DEGRADATION IN A BLOOD FLOW | 2015 |
|
RU2605385C2 |
| PEG-CONTAINING CONJUGATES OF HGF-NK4 | 2002 |
|
RU2293574C2 |
| NEW FUNCTIONAL, HIGH-PURITY STABLE CONJUGATE OF GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) AND POLYETHYLENE GLYCOL WITH PROLONGED BIOLOGICAL ACTION, APPLICABLE FOR MEDICAL PURPOSES, AND BASED IMMUNOBIOLOGICAL AGENT | 2010 |
|
RU2446173C1 |
| INSULINOTROPIC COMPLEX IN WHICH IMMUNOGLOBULIN FRAGMENT IS USED | 2008 |
|
RU2436589C2 |
| PEG-CONTAINING POLYPEPTIDE T1249 | 2003 |
|
RU2294938C2 |
| NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON | 2010 |
|
RU2447083C1 |
| PEG DENDRIMER WITH FOUR BRANCHES FOR CONJUGATION WITH PROTEINS AND PEPTIDES | 2006 |
|
RU2409389C2 |
| INSULIN CONJUGATE WITH APPLICATION OF IMMUNOGLOBULIN FRAGMENT | 2011 |
|
RU2519073C1 |
| CONJUGATE CONTAINING OXINTOMODULIN AND IMMUNOGLOBULIN FRAGMENT, AND ITS APPLICATION | 2012 |
|
RU2733544C2 |
